ArticleBMC genomic data2026
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with elevated mean corpuscular volume (MCV) and bilirubin.
Article in BMC genomic data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlucose-6-phosphate dehydrogenase (G6PD) deficiency is a common hereditary hemolytic disorder. To provide evidence for the clinical evaluation and management of this disorder, we investigated the differences in erythrocyte and biochemical parameters between G6PD-deficient and G6PD-normal individuals. After excluding samples with positive preliminary thalassemia screening, anemia, or liver dysfunction, a total of 2,582 health checkup individuals, 236 male military conscripts, and 3,125 males undergoing preconception check-ups were enrolled. All subjects were divided into a G6PD-normal group (G6PD-N group) and a G6PD-deficient group (G6PD-D group) using G6PD/6PGD ratio or quantitative G6PD activity assay. Statistical analyses were performed to compare erythrocyte and biochemical parameters between the two groups. Additionally, 151 samples with macrocytosis (mean corpuscular volume [MCV] > 100 fL) were subjected to G6PD/6PGD determination and genetic testing to investigate the prevalence of G6PD deficiency in this subpopulation.
resultsAcross all study populations, MCV and bilirubin were significantly higher in the G6PD-D group than in the G6PD-N group (p < 0.05). Except for the female health checkup group (G6PD activity), red blood cell (RBC) counts were lower in the G6PD-D group in all other populations. In addition, hemoglobin (HGB) levels were significantly lower in the G6PD-D group in the health checkup population (G6PD/6PGD method) (p < 0.05). Among the 151 "healthy" macrocytosis samples, 90 cases (59.60%, 90/151) were identified as G6PD-deficient, representing a significantly higher prevalence compared to the general study population.
conclusionsReduced erythrocyte survival induced by G6PD deficiency may trigger compensatory bone marrow hyperplasia, which increases the proportion of newly synthesized erythrocyte and thereby elevates MCV. In endemic areas of G6PD deficiency, a marked increase in MCV may serve as a potential indicator for the diagnosis of G6PD deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.